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Abstract
Pain in cancer is often underdiagnosed and undertreated. Breakthrough pain, in particular, severely impacts the quality of life of
patients. In this study, we evaluated management and care of pain in Spain from the patient perspective by assessing the
experience of 275 patients who had suffered breakthrough pain. Although most patients had suffered moderate-to-severe pain
in the last 24 hours, pain relief was achieved in the majority of cases. The body areas with a higher pain intensity was felt varied
based on primary cancer. Adherence to treatment was subpar, and patients were moderately concerned about addiction to
treatment and adverse events. Doctors did not assess pain in every visit and there is room for improvement in its classification.
Education strategies directed toward patients and health care personnel are needed to improve pain assessment, follow-up,
and compliance. These could guide shared decision-making and improve communication about cancer pain to improve its care.
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Introduction
Pain is a major source of distress associated with cancer and
it significantly impacts patients’ quality of life, diagnosis
and treatment (1). Although its prevalence varies between
studies, it has been estimated that 55% of cancer patients
undergoing treatment feel pain (2). Pain can be classified
in multiple ways by evaluating domains such as location,
intensity, temporal pattern, pathophysiology, and etiology
(3,4). However, not all domains are evaluated in all cases,
nor are other relevant aspects, such as characteristics of the
disease (primary diagnosis, extent of the disease, metasta-
sis), demographics, and psychological status (3).
In order to provide an adequate and personalized treat-
ment of pain, it must be properly assessed and understood.
One major type is breakthrough cancer pain (BTP), which is
a “transitory exacerbation of pain that occurs, either sponta-
neously or associated with predictable factors or not, even
though the baseline pain is relatively stable and well con-
trolled” (5). The definition of BTP is still a source of debate,
and there is variability on what constitute its minimum
intensity, duration, and number of flares (6–8). Additionally,
not all clinicians consider opioids should be used to control
this pain (6). The pathophysiology of BTP is heterogeneous,
but the 2 main subtypes are incident pain (either voluntary,
involuntary or intervention-related) and spontaneous pain
(which is unpredictable) (9). The prevalence of BTP varies
between studies (10), but its presence is associated with
higher pain intensity, functional impairment, and a signifi-
cant impact on quality of life (11,12). High prevalence rates
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of BTP in cancer patients were found in 2 recent studies in
Spain, one of which notably showed that these high rates
were not expected by doctors (13,14).
Although management of cancer pain has improved in
recent years, it is still an ongoing challenge, with clinician
and patient barriers—among others—that need to be over-
come (15). A third of patients are found to be undertreated
for pain (16). On this note, a study of 12 countries, not
including Spain, found that 12% of patients reported health
care professionals did not regard pain as a problem, and 50%
perceived clinicians did not consider their quality of life to
be important (17).
The Spanish Foundation for Excellence and Quality in
Oncology (Fundación ECO) is committed to improving care
of cancer patients. To this end, Fundación ECO directed this
patient-centered study to understand their experience and
unmet needs regarding pain. The aim of this article is to
present the findings of the surveys carried out on pain
(including BTP), the care received, the degree to which pain
management was achieved, and the impact on quality of life




This was a cross-sectional, multicenter, study. To calculate
the sample size needed, we considered a margin of error of
6%, a 95% level of confidence, and a response distribution of
50%. This resulted in a required sample size of 275 patients.
To guarantee this number was achieved in the event of pos-
sible withdrawals, 47 oncologists were invited to participate,
their number being proportional to the population of their
respective regions. Each oncologist recruited 4 to 6 patients
until the required sample size of 275 was reached. From the
study starting date, for 4 to 6 consecutive days, the first
eligible patient of each day was asked to participate in this
study. All patients provided written informed consent. Inclu-
sion criteria were patients who were: over 18 years old;
suffering from pain associated with cancer, including BTP;
and, if taking analgesics, having initiated treatment at least
1 month prior to inclusion in this study. The only exclusion
criterion was the patient’s lack of consent to participate.
An ad hoc questionnaire was provided to oncologic
patients to assess pain associated with cancer, including
BTP. Each oncologist collected the anonymized question-
naires and, once the last one was received, patient data were
aggregated and recorded in a restricted-access online repo-
sitory platform designed for this study. There was no patient
follow-up after the questionnaire was submitted.
Due to the nature of the study, submission to the Spanish
Agency of Medicines and Medical Products was not
required. Nevertheless, this study was performed in accor-
dance with the Declaration of Helsinki and submitted to the
clinical research ethics committee, who issued a favorable
opinion.
Variables Studied
Descriptive patient variables were recorded: demographics
(age, sex, level of education, autonomous region of Spain)
and clinical variables (type of cancer, pain associated with
cancer [type, intensity, location, and progression], and
impact on quality of life). Descriptive patient opinion vari-
ables were also recorded: attitude toward pain on the part of
the oncologist and other health care professionals, quality of
information received regarding pain and possible treatment,
pain follow-up, adherence to recommended treatments,
degree of personalization received, and general satisfaction
with care compared with the patient’s expectations.
Data Analysis
Continuous variables were described using means + SD,
using medians and ranges in cases of large dispersion of data.
Categorical variables were described using frequencies and
CIs. Continuous variables were compared using independent
t tests or Mann–Whitney U tests, as appropriate. All statis-




A total of 47 oncologists participated in this study
(27 women, 20 men), with an average age of 38.9 (95%
CI: 36.8-41.0) years and a median age of 38 (range,
30-55). No significant difference in age was found between
women (39.0 years) and men (38.7 years; P ¼ .094). Profes-
sional experience ranged from 2 to 28 years, with an average
of 11.9 (95% CI: 10.1-13.7) and a median of 10 years. There
was no significant difference in work experience between
women (12.1 years) and men (11.7 years; P ¼ .650). Most
oncologists (46, 97.9%) worked in the public health care
system, 3 of them in combination with private practice; only
1 oncologist worked exclusively in a private hospital. Oncol-
ogists saw an average of 20.4 (95% CI: 12-25) patients per
day, with 30.5% of them reporting BTP.
Patient Demographics
A total of 275 patients representing 11 of the 17 autonomous
regions of Spain were included in this study (Table 1). The
average age was 62.4 (95% CI: 61.0-63.7) years and ranged
from 19 to 86. Of these, 46.5% were women. Regarding
education level, 14.2% had no studies, 36.0% had primary
level studies, and 16.0% had a university degree. The most
common primary tumor was lung (77, 28.0%), followed by
breast (42, 15.3%) and colorectal (36, 13.1%).
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At the time of inclusion in the study, a considerable
number of patients (250, 90.9%) felt pain. Most patients
(190, 69%) reported feeling both chronic pain and BTP
throughout the disease, while 38 (13.8%) and 47 (17.1%)
felt only either BTP or chronic pain, respectively.
Pain Description
Patients reported the specific body area where they felt the
most severe pain. Among all cancer types, the most common
areas for pain were the abdomen (22.5%), torso (9.8%), neck
(6.6%), spine (6.2%), and hips (5.8%) (Table 2). The most
affected areas differed based on the primary cancer, with
lung cancer patients feeling most pain in the spine (13%)
and the lumbar area (11.7%), breast cancer patients feeling
most pain in the lumbar area (23.8%) and the hips (19.1%),
and colorectal cancer patients feeling most pain in the abdo-
men (66.7%).
Patients reported the minimum, average, and maximum
pain they had felt in the previous 24 hours on a scale from 0
(lowest) to 10 (highest; Figure 1). Almost half (127, 46.2%)
of patients reported a maximum pain of 8. Almost 70% of
patients (192, 69.8%) felt an average pain between 3 and 6,
and also a minimum pain under 3 (195, 70.1%).
Patients reported feeling pain for an average of 10.3 (95%
CI: 8.8-11.8) months and a median of 6 (range, 0.5-84)
months. The average time patients had experienced BTP was
6.5 (95% CI: 5.1-7.6) months, with a median of 3 months
(range, 0.3-6). Only 3 patients reported feeling no BTP.
When questioned about the cause of pain, 179 (65.1%)
patients believed their pain was related only to the cancer,
and 63 (22.9%) attributed it to both the cancer and the cancer
treatment. Only 22 (8%) patients believed their pain was
caused by the cancer treatment alone, and the remaining
11 (4%) patients attributed their pain to other causes or did
not respond.
Impact of Pain on Patient Quality of Life
Patients reported the degree to which pain had affected their
life, on a scale from 0 (not affected) to 10 (severely affected),
in the following: general activity, mood, walking, work,
relationships, sleep, and life enjoyment. The domains most
affected were life enjoyment (average score, 6.34), general
activity (6.31), and mood (6.2). Lower average scores were
given to impact on work (6.03), relationships (5.03), and
sleep (5.47), with the lowest score being for walking (4.98).
Care received for Pain
Most (213, 77.5%) patients reported being informed at diag-
nosis of the possibility of feeling pain associated with can-
cer, 31 (11.3%) patients reported not receiving this
information, and another 31 (11.3%) did not remember.
Most (227, 82.5%) patients also reported their oncologist
informed them that pain can be controlled, while
24 (8.7%) patients said they were not informed of this, and
another 24 (8.7%) did not remember.
Regarding monetarization of pain, 197 (72.9%) patients
reported their doctor asked about it on every visit,
52 (19.3%) said it happened in most visits, 7 (2.6%) reported
they were asked about it in less than half the visits, and
14 (5.2%) reported only occasionally being asked about
pain. No patient reported not having been asked. Pain dis-
cussion was most commonly initiated by doctors (41.7%)
than by patients (25.4%). Only in 16.9% of cases did the
doctor ask about pain intensity; in 10.8% of total cases, the
doctor examined the patient.
Oncologists were the main health care professionals
(65%) involved in treating pain associated with cancer, fol-
lowed by primary care doctors (11.0%), palliative care doc-
tors (5.1%), anesthetists or pain unit doctors (4.9%), and
radiation oncologists (4.6%).
Perspectives on Pain Relief Medication
Satisfaction with pain relief treatment was high, with 113
(43.1%) patients reporting being very satisfied and 133
(50.8%) being quite satisfied. Addiction to treatment was a
cause for concern in almost half of patients, who were either
very worried (38, 13.8%) or quite worried (80, 29.1%) about
it. Additionally, over half of patients were either very
Table 1. Patient Characteristics.
N (%)
N ¼ 275
Age, average years (95% CI) 62.4 (61.0-63.7)
Gender, female 128 (46.5)
Education level
No schooling 39 (14.2)
Primary 99 (36.0)
Junior high school 40 (14.5)


















Chronic and breakthrough 190 (69.1)
aNo pain at the time the patient was included in the study, other than
common headaches, toothaches, contusions, and so on.












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































worried (36, 13.1%) or quite worried (110, 40.0%) about the
adverse events of pain relief treatment.
Questions about adherence to pain relief treatment
showed that 46 (16.7%) patients sometimes forgot to take
the medication, 48 (17.5%) did not take it at the indicated
time, 87 (31.6%) stopped taking it once they felt better,
and 142 (51.6%) stopped taking it if it did not agree with
them. However, regarding treatment for BTP, almost all
(264, 96%) patients followed treatment guidelines.
Regarding chronic pain management in the 24 hours prior
to the patients’ visit, 191 (69.5%) patients reported relief
over 70%. Eight (2.9%) patients experienced no or minimal
relief, under 20%. In the case of BTP, 204 (74.2%) patients
reported relief over 70%, and 7 (2.5%) patients experienced
no or minimal relief, under 20%.
When asked about their degree of satisfaction with pain
relief treatment, only a small percentage of patients reported
being quite or very unsatisfied with the effectiveness
of treatment (36, 13.1%), tolerance of adverse effects
(43, 15.6%), and overall treatment (34, 12.4%).
Discussion
In this study, we evaluated the pain care that cancer patients
receive in Spain from a patient-centered perspective. We
found that most patients had suffered moderate-to-severe
pain in the last 24 hours and had suffered from pain for an
average of 10.3 months. We assessed the impact of pain on
quality of life, adherence to treatment, and doctor attitudes
to understand the different aspects involved in pain
management.
A systematic review found the average prevalence of
BTP was 61.0%, although there was high variability between
studies, ranging 33.3% to 95.0%, with higher rates corre-
sponding to patients in hospice (10). A recent study in Spain
found that 91.3% of cancer patients with pain had suffered
from BTP, although almost half of them had been undetected
by doctors (13.) Our study did not address prevalence
of BTP, as one of our inclusion criteria was that patients
had suffered BTP at some point, although 3 of them
later reported in the questionnaire that they had not
experienced it.
The body areas where patients felt most pain varied
depending on the primary cancer, in agreement with reports
by others (18). Overall pain prevalence has also been found
to vary based on primary cancer (14,17); however, we did
not evaluate this due to the data being aggregated.
In contrast to the finding that pain is undertreated in
approximately a third of cancer patients (16), most patients
(93.9%) in our study were satisfied with the pain relief
achieved with medication. This finding is also higher than
a previous study in Spain, reporting that almost half of
patients with BTP did not achieve pain control (14). While
we observed that 96% of patients adhered to treatment for
BTP, adherence to chronic pain treatment was subpar, with 1
in 6 patients forgetting to take the medication. The main
patient barrier to adherence was negative side effects, with
over half of patients not taking the medication for this rea-
son. Patient education has proven to improve quality of life
and adherence to treatment for cancer pain (19–21) and to
decrease pain intensity (19–23). Future work in Spain could
focus on carrying out patient education strategies using
Figure 1. Pain severity in the last 24 hours.
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several methods (21): face-to-face coaching sessions,
follow-up phone calls, and informational videos, among oth-
ers. These initiatives could target patient compliance and
educate on opioid treatment, its associated adverse events,
and addiction, as these were a cause for concern for approx-
imately half of patients in our study, which is in agreement
with reports from other countries (24–27).
Education of all health care personnel should also be
considered, given that, in 35% of cases, patients reported
that pain was not followed by an oncologist. Patients also
reported the doctors examined them in only 10.8% of cases
and assessed pain intensity in 16.9% of cases. On this note,
oncologists in this study saw an average of 20.4 patients
per day, a third of them reporting BTP, and a recent Delphi
survey found that Spanish oncologists considered limited
time to evaluate patients to be a barrier to managing
BTP (28). Classifying pain in all of its domains can provide
more information and improve understanding of patient
needs to, ultimately, deliver a higher quality of pain care.
Studies have shown that physicians consider there are defi-
ciencies in pain management training (29–31). On this note,
a study in Spain found that almost half of oncologists had not
read the guidelines on diagnosis and treatment of BTP (13).
This further highlights the need to not only educate patients
but also health care professionals. Additionally, significant
differences were found on nurses’ training on pain manage-
ment across 12 European countries (32). Initiatives to
improve pain management by health care professionals
could include mandatory palliative care rotations for trai-
nees, developing multidisciplinary teams, creating educa-
tional courses, and encouraging interdisciplinary work
(33). Most patients desire shared decision-making in pain
management (34), which leads to more open communication
and higher patient satisfaction (35).
This study provides, for the first time, the patient perspec-
tive on management of pain associated with cancer in Spain.
We believe our findings can be useful for health care pro-
fessionals and decision makers to better understand and
address patient needs. They can also serve as a basis for
implementing policies that address the issues found, such
as the need for evaluating pain in several ways, most notably
examining the patient and grading pain intensity. We suggest
placing a stronger focus on education of patients and health
care professionals, and implementing strategies that encour-
age open communication about pain.
Limitations
The main limitation of this study is the use of aggregated
data of patient reports, which precludes establishing associa-
tions between the parameters evaluated. For example, study-
ing the association between type of primary cancer and pain
intensity, or that between information provided by the doctor
and adherence to treatment could help develop guidelines
and strategies toward personalization of pain care. Also, our
sample size is relatively small, with a predominance of
3 cancer types (lung, breast, and colorectal). Future studies
that address these limitations could further establish links
between the parameters evaluated here and improve pain
management. Finally, this study reports the experience of
patients and their opinions; however, we cannot confirm the
information they report, and we cannot rule out a possible
bias in their expectations of care.
Conclusion
We evaluated the perspective of cancer patients in Spain
regarding care of pain and found that, although almost half
of them had felt a very high maximum pain in the previous
24 hours, the vast majority were satisfied with the degree of
pain management achieved with analgesics. The body areas
where patients felt most pain were the abdomen, torso, neck,
spine, and hips, predominance varying with primary cancer
type. The dimension of quality of life that patients consid-
ered were more affected by pain was life enjoyment and
general activity. Our findings highlight some areas of
improvement in pain management and could guide strategies
that address them.
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